Table 6.
Gastrin levels from baseline (pg/mL) during treatment and follow‐up periods of the gastric and duodenal ulcer studies (safety analysis set)
| Variable | GU study | DU study | ||||||
|---|---|---|---|---|---|---|---|---|
| Vonoprazan (N = 244) | Lansoprazole (N = 238) | Vonoprazan (N = 183) | Lansoprazole (N = 185) | |||||
| N | Mean (s.d.) | N | Mean (s.d.) | N | Mean (s.d.) | N | Mean (s.d.) | |
| Treatment period | ||||||||
| Baseline | 242 | 156.3 (181.6) | 238 | 147.2 (124.9) | 182 | 117.1 (103.3) | 183 | 118.2 (84.2) |
| Week 2 | 239 | 330.7 (351.9) | 237 | 245.4 (212.0) | 179 | 372.8 (253.1) | 185 | 261.2 (226.3) |
| Week 4 | 159 | 353.4 (274.3) | 151 | 256.3 (173.3) | 53 | 437.3 (272.4) | 64 | 295.6 (255.0) |
| Week 6 | NA | NA | NA | NA | 4 | 514.3 (255.9) | 8 | 245.8 (177.5) |
| Week 8 | 54 | 394.1 (307.3) | 52 | 289.3 (250.3) | NA | NA | NA | NA |
| Follow‐up | ||||||||
| Week 2 | 209 | 134.4 (103.3) | 205 | 153.9 (120.6) | 166 | 104.9 (69.8) | 173 | 123.9 (145.8) |
| Week 4 | 26 | 202.5 (89.9) | 41 | 216.5 (136.4) | 10 | 206.9 (134.4) | 19 | 204.6 (153.1) |
| Week 6 | NA | NA | NA | NA | 4 | 229.8 (148.1) | 5 | 339.4 (239.5) |
| Week 8 | 10 | 199.3 (129.7) | 12 | 199.3 (83.3) | NA | NA | NA | NA |
DU, duodenal ulcer; GU, gastric ulcer; NA, not applicable; s.d., standard deviation.